These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 2100567)
1. Tumor markers of head and neck carcinoma. Eibling DE; Wagner RL; Johnson JT Immunol Ser; 1990; 53():357-83. PubMed ID: 2100567 [TBL] [Abstract][Full Text] [Related]
2. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck. Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093 [TBL] [Abstract][Full Text] [Related]
3. [Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck]. González Sánchez E; López-Ríos Velasco J; Calvo Boizas E; García-Talavera Fernández JR; Martín Ro-dríguez M; Muñoz Herrera A; Del Cañizo Alvarez A Acta Otorrinolaringol Esp; 1999 Mar; 50(2):85-9. PubMed ID: 10217679 [TBL] [Abstract][Full Text] [Related]
4. [The diagnostic value of the tumor markers CEA, "Ca 19-9", "Ca 125", "Ca15-3" and "SCC" for the detection of recurrent tumors in patients with tumors of the head and neck]. Zöller J; Fiehn W; Mende U; Hotz G Dtsch Z Mund Kiefer Gesichtschir; 1990; 14(4):254-9. PubMed ID: 2134649 [TBL] [Abstract][Full Text] [Related]
5. [Clinical evaluation of tumor markers in head and neck squamous cell carcinomas]. Yoneda K; Hirota J; Yamamoto T; Ueta E; Osaki T Gan No Rinsho; 1990 Mar; 36(4):458-64. PubMed ID: 2181163 [TBL] [Abstract][Full Text] [Related]
6. [Squamous cell carcinoma antigen. Current clinical value of a new tumor marker in head and neck cancer; preliminary results of a prospective study after 12 months]. Clasen B; Roettger D; Senekowitsch R; Menz E Laryngol Rhinol Otol (Stuttg); 1988 Aug; 67(8):420-5. PubMed ID: 3210877 [TBL] [Abstract][Full Text] [Related]
7. [Role of the tumor marker TAG-72 in head and neck neoplasms]. Altissimi G; von Garrel C HNO; 1990 Oct; 38(10):364-6. PubMed ID: 2283330 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC. Molina R; Torres MD; Moragas M; Filella X; Jo J; Giménez N; Traserra J; Ballesta AM Anticancer Res; 1995; 15(2):479-84. PubMed ID: 7763026 [TBL] [Abstract][Full Text] [Related]
9. [Relevance of the new tumor marker SCC (squamous cell carcinoma antigen) for the diagnosis and follow-up control of squamous epithelial carcinoma of the head and neck]. Koch T; Eiffert H; Spindler MB HNO; 1989 Nov; 37(11):454-9. PubMed ID: 2584067 [TBL] [Abstract][Full Text] [Related]
10. Antibody responses to survivin and their clinical significance in patients with head and neck cancer. Eto M; Kodama S; Uemura N; Suzuki M Head Neck; 2007 Dec; 29(12):1128-35. PubMed ID: 17636541 [TBL] [Abstract][Full Text] [Related]
11. Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN). Niemann AM; Goeroegh T; Gottschlich S; Lippert BM; Werner JA Anticancer Res; 1997; 17(4B):2859-60. PubMed ID: 9329547 [TBL] [Abstract][Full Text] [Related]
12. SCC-RIA in the diagnosis of squamous cell carcinoma of the head and neck. Eibling DE; Johnson JT; Wagner RL; Su S Laryngoscope; 1989 Feb; 99(2):117-24. PubMed ID: 2913421 [TBL] [Abstract][Full Text] [Related]
13. Serum sialic acid forms as markers for head and neck malignancies. Bhatavdekar JM; Vora HH; Patel DD Neoplasma; 1988; 35(4):425-34. PubMed ID: 3185839 [TBL] [Abstract][Full Text] [Related]
14. A new prognostic indicator for head and neck cancer--p53 serum antibodies? Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224 [TBL] [Abstract][Full Text] [Related]
15. Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer. Maass JD; Hoffmann-Fazel A; Goeroegh T; Hoffmann M; Meyer JE; Gottschlich S; Rudert H; Maune S Anticancer Res; 2000; 20(3B):2241-3. PubMed ID: 10928185 [TBL] [Abstract][Full Text] [Related]
16. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. Kuropkat C; Werner JA J Laryngol Otol; 2003 Dec; 117(12):1007-8; author reply 1008-9. PubMed ID: 14738621 [No Abstract] [Full Text] [Related]
17. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients. Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of serum tumor markers in head and neck cancer. Martin M; Rayo JI; Talavera JR; Muñoz A; Cañizo A J Nucl Med Allied Sci; 1990; 34(4 Suppl):235-8. PubMed ID: 2092125 [No Abstract] [Full Text] [Related]
19. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. Deng YF; Chen P; Lin YZ; Le JZ; Wu XL; Yu MQ; Zhuang PY; Gao MH J Laryngol Otol; 2003 Mar; 117(3):190-4. PubMed ID: 12648374 [TBL] [Abstract][Full Text] [Related]
20. [The effect of the microenvironment of head and neck cancers on tumor progression]. Lukits J Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]